首页> 外文OA文献 >Dual Carfilzomib and Doxorubicin–Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple Myeloma

【2h】

Dual Carfilzomib and Doxorubicin–Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple Myeloma

机译：双砂蛋白和多柔比蛋白加载的脂质体纳米粒子，用于多发性骨髓瘤的协同疗效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Jonathan D. Ashley; Charissa J. Quinlan; Valerie A. Schroeder; Mark A. Suckow; Vincenzo J. Pizzuti; Tanyel Kiziltepe; Basar Bilgicer;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Dual Carfilzomib and Doxorubicin-Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple Myeloma [J] . Ashley Jonathan D., Quinlan Charissa J., Schroeder Valerie A., Molecular cancer therapeutics . 2016,第7期

机译：双卡非佐米和阿霉素脂质体纳米颗粒在多发性骨髓瘤中的协同功效。
2. Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo [J] . Ashley Jonathan D., Stefanick Jared F., Schroeder Valerie A., Journal of Controlled Release: Official Journal of the Controlled Release Society . 2014,第Null期

机译：脂质体卡非佐米纳米颗粒可有效靶向多种骨髓瘤细胞，并在体内显示出增强的功效
3. A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma [J] . Schroeder Mark A., Fiala Mark A., Huselton Eric, Clinical cancer research: an official journal of the American Association for Cancer Research . 2019,第13期

机译：用于治疗复发/难治多骨髓瘤的Carfilzomib，Pegymated脂质体Doxorubicin和地塞米松的I / II试验
4. Enhanced efficacy of anti-tumor liposomal doxorubicin by hyperthermia [C] . Ping Liu, Lisa Xuemin Xu, Aili Zhang . 2006

机译：热疗增强抗肿瘤脂质体阿霉素的功效
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety [O] . Yujia Zhai, Dai Yuan, Xueling Ge, 2021

机译：基于Vindesine的和基于Bortezomib的患者的Pegylated脂质体DOXORUBICIN用于新诊断的多发性骨髓瘤的患者：疗效和安全的回顾性研究
7. Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: Effects of adverse prognostic factors on outcome [O] . Bladé Joan, San Miguel Jesús F. 2012

机译：聚乙二醇脂质体阿霉素联合硼替佐米治疗多发性骨髓瘤的疗效和安全性：不良预后因素对预后的影响

Dual Carfilzomib and Doxorubicin–Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple Myeloma

著录项

引文网络

相似文献

相关主题

期刊订阅